Allstocks.com's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Hot Stocks Free for All ! » UGNE News

 - UBBFriend: Email this page to someone!    
Author Topic: UGNE News
DiQuiRiesco
Member


Icon 1 posted      Profile for DiQuiRiesco     Send New Private Message       Edit/Delete Post   Reply With Quote 
Unigene Announces Licensing and Manufacturing Agreements for Calcitonin with Novartis; Unigene Eligible to Receive $18.7 Million in Addition to Royalties
FAIRFIELD, N.J., Apr 8, 2004 (BUSINESS WIRE) --

Unigene Laboratories, Inc. (OTCBB: UGNE) has signed licensing and clinical supply agreements with Novartis Pharma AG (NYSE: NVS) to provide for the recombinant production of calcitonin, the active ingredient used in various formulations for the treatment of osteoporosis. Under the terms of these agreements Unigene is eligible to receive $18.7 million, including an initial payment of $5.6 million. In addition, Unigene is eligible to receive royalties on sales of any current or future Novartis products that will contain calcitonin made using Unigene's process.

The license agreement grants Novartis a worldwide license to produce recombinant calcitonin under Unigene's patented process for manufacturing recombinant peptides. Unigene will sell calcitonin to Novartis to support Novartis' development programs. Unigene remains free to develop and commercialize its own products containing calcitonin, including its oral product under development and FORTICAL(R), its nasal product that recently received an approvable letter from the U.S. Food and Drug Administration.

"This arrangement will allow Unigene and Novartis to independently advance their commercial interests in calcitonin using the same production platform," commented Dr. Warren Levy, President and CEO of Unigene. "Our patented manufacturing process allows for the cost-effective large-scale production of peptides to support their worldwide commercialization as oral or nasal therapeutics. In addition to potentially providing a highly desirable revenue stream, the agreements provide Unigene with a potential source of supply for recombinant calcitonin that far exceeds our current capacity, thereby avoiding the need for significant capital expenditures for construction of a larger production facility. This increased supply of recombinant calcitonin will be essential to support the development and commercialization of our oral calcitonin product."

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Unigene has licensed the U.S. rights for its nasal calcitonin product to Upsher-Smith Laboratories and the worldwide rights for its oral PTH technology to GlaxoSmithKline. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.'s management's current expectations, estimates, beliefs, assumptions, and projections about Unigene's business and industry. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene's cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene's Securities and Exchange Commission filings.

SOURCE: Unigene Laboratories, Inc.

Investor Contact:
The Investor Relations Group
Damian McIntosh/Dian Griesel, Ph.D., 212-825-3210

Customize your Business Wire news & multimedia to match your needs.
Get breaking news from companies and organizations worldwide.
Logon for FREE today at www.BusinessWire.com.

Copyright (C) 2004 Business Wire. All rights reserved.


Posts: 1019 | From: Are You With The CIA? | Registered: Dec 2003  |  IP: Logged | Report this post to a Moderator
glassman
Member


Icon 1 posted      Profile for glassman     Send New Private Message       Edit/Delete Post   Reply With Quote 
73 milion shares as of 12-31-03---

financials very typical of start-up type bio-tech negative cash flow but decreasing the bleeding---not a hold but could be good pop today---


Posts: 36378 | From: USA | Registered: Sep 2003  |  IP: Logged | Report this post to a Moderator
DiQuiRiesco
Member


Icon 1 posted      Profile for DiQuiRiesco     Send New Private Message       Edit/Delete Post   Reply With Quote 
That's my thinking, MM's already starting to move around, NITE is well above ask and on bid.


Posts: 1019 | From: Are You With The CIA? | Registered: Dec 2003  |  IP: Logged | Report this post to a Moderator
glassman
Member


Icon 1 posted      Profile for glassman     Send New Private Message       Edit/Delete Post   Reply With Quote 
ASK is up .04$ already----may not be a good idea to buy until about 9:55 EST--i won't chase it before the open....
Posts: 36378 | From: USA | Registered: Sep 2003  |  IP: Logged | Report this post to a Moderator
DiQuiRiesco
Member


Icon 1 posted      Profile for DiQuiRiesco     Send New Private Message       Edit/Delete Post   Reply With Quote 
tell me about it, already up to .80 with fifteen minutes to go



Posts: 1019 | From: Are You With The CIA? | Registered: Dec 2003  |  IP: Logged | Report this post to a Moderator
glassman
Member


Icon 1 posted      Profile for glassman     Send New Private Message       Edit/Delete Post   Reply With Quote 
oh well--------the MM's are gonna take all the profits on the open it looks like....
Posts: 36378 | From: USA | Registered: Sep 2003  |  IP: Logged | Report this post to a Moderator
DiQuiRiesco
Member


Icon 1 posted      Profile for DiQuiRiesco     Send New Private Message       Edit/Delete Post   Reply With Quote 
quote:
Originally posted by glassman:
oh well--------the MM's are gonna take all the profits on the open it looks like....

nevermind about waiting, in at .88


Posts: 1019 | From: Are You With The CIA? | Registered: Dec 2003  |  IP: Logged | Report this post to a Moderator
glassman
Member


Icon 1 posted      Profile for glassman     Send New Private Message       Edit/Delete Post   Reply With Quote 
DQR---great call man---i waited for it to come back to me and i was wrong--LOL

maybe next one will work my way--good luck with it....


Posts: 36378 | From: USA | Registered: Sep 2003  |  IP: Logged | Report this post to a Moderator
Repoman75
Member


Rate Member
Icon 1 posted      Profile for Repoman75         Edit/Delete Post   Reply With Quote 
Radaring...

Unigene to Present at the UBS Global Life Sciences Conference on September 27, 2006
Tuesday September 19, 8:30 am ET


FAIRFIELD, N.J.--(BUSINESS WIRE)--Sept. 19, 2006--Unigene Laboratories, Inc.'s (OTCBB: UGNE - News) President and CEO, Dr. Warren Levy, will speak at the 8th Annual UBS Global Life Sciences Conference on Wednesday, September 27, 2006 at 11:00 A.M. Dr. Levy will present information on Unigene's products and collaborations to analysts, portfolio managers, investment bankers and other financial professionals. The conference will be held at The Grand Hyatt in New York City from September 25-28, 2006.

A live audio webcast of the presentation will also be available on the UBS website at www.ibb.ubs.com under the "conference" tab. An audio replay of the presentation will begin three hours after the presentation time and will be available until October 28, 2006.

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical®, Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical® to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call (973) 882-0860 or visit www.unigene.com. For information about Fortical, visit www.fortical.com.

--------------------
Stick with Repo's plan in '07 - FRPT/DKAM!

Posts: 6379 | From: PA | Registered: Dec 2004  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share